Support legislation to make the lower drug prices negotiated by Medicare available to Americans with private insurance, not just Medicare beneficiaries
Seth will support legislation to make Medicare-negotiated lower drug prices available to Americans with private insurance.
Occurrences
will fight for legislation to allow Medicare to negotiate drug prices with the pharmaceutical companies
Evidence
Congress.gov says Rep. Seth Magaziner was a cosponsor of H.R.4895, and the bill summary states it would expand the Medicare Drug Price Negotiation Program to drugs covered under private insurance and apply negotiated maximum prices to private health insurance unless the insurer opts out.
Congress.gov lists Rep. Seth Magaziner as the sponsor of H.R.5924, titled the Lower Drug Costs Today Act; the bill status remains introduced and referred to subcommittee, with no enactment.
Congress.gov lists Rep. Seth Magaziner as sponsor of H.R.5924. The bill was introduced in the House and referred to the Subcommittee on Health; its purpose was to extend Medicare-negotiated drug prices into private insurance.
Congress.gov's cosponsors record shows Rep. Magaziner joined H.R.4895 on 2023-08-08. The underlying bill would apply Medicare-negotiated drug prices to private insurance plans unless insurers opt out.
Assessments
The promise was to support legislation extending Medicare-negotiated lower drug prices to people with private insurance. As a sitting U.S. representative, Seth Magaziner fulfilled that support promise in the same term by cosponsoring H.R. 4895 and sponsoring H.R. 5924, both aimed at applying Medicare-negotiated prices to private insurance. Because the pledge was about legislative support rather than guaranteeing enactment, his direct sponsorship and cosponsorship count as delivery even though the bills did not become law.
The promise was to support legislation, not necessarily to enact the policy. During his House term, Magaziner sponsored H.R.5924 and cosponsored H.R.4895, both aimed at extending Medicare-negotiated lower drug prices to people with private insurance. Although the bills were not enacted, his sponsorship and cosponsorship satisfy the promised action in federal office context.